Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Neutrophils are known to externalize their DNA and intracellular contents to neutralize invading pathogens. This process may enhance blood coagulation during inflammation. Tissue factor (TF) pathway inhibitor (TFPI) binds to extracellular DNA and may be citrullinated by peptidylarginine deiminase 4. Citrullination of TFPI reduces its anticoagulant activity toward factor (F)Xa but appears to retain its inhibition of TF-triggered thrombin generation, indicating differential regulation of TFPI functions by peptidylarginine deiminase 4.

Objectives: This work aimed to study the effects of citrullination of TFPI-alpha on the inhibition of FXa, FVIIa/TF, and the cofactor activity of protein S.

Methods: The effect of TFPI citrullination on the inhibition of FXa and FVIIa/TF was measured by chromogenic assays using purified components and by calibrated automated thrombography. Interaction with protein S was assessed by surface plasmon resonance and solid-phase binding assays using immobilized protein S, recombinant TFPI, and synthetic TFPI domains.

Results: Citrullination of TFPI abolished its ability to inhibit FXa- and FXIa-triggered thrombin generation. However, its impaired inhibition of TF-triggered thrombin generation was still enhanced by protein S. Chromogenic assays revealed that citrullinated TFPI was essentially inactive as an inhibitor of the FVIIa-TF complex in the absence of protein S but partially restored by protein S. Interaction studies revealed that binding of citrullinated TFPI to protein S was reduced approximately 4-fold.

Conclusion: Citrullinated TFPI shows impaired natural anticoagulant activity. While anti-FXa activity is essentially absent, its anti-TF/FVIIa activity can still be enhanced by protein S. This enhancement is incomplete; however, protein S binding to citrullinated TFPI is impaired.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtha.2024.11.009DOI Listing

Publication Analysis

Top Keywords

citrullinated tfpi
16
anticoagulant activity
12
thrombin generation
12
tfpi
11
protein
10
tissue factor
8
factor pathway
8
pathway inhibitor
8
peptidylarginine deiminase
8
natural anticoagulant
8

Similar Publications

Article Synopsis
  • - Neutrophils can release their DNA and contents to fight infections, but this can impact blood coagulation through a protein called TFPI, which is affected by an enzyme (PAD4) that alters (citrullinates) it, reducing its ability to prevent blood clotting.
  • - The study aimed to explore how this citrullination affects TFPI's performance in inhibiting key components of blood coagulation, specifically FXa and the FVIIa/tissue factor complex, using various laboratory techniques.
  • - Results showed that while citrullination severely weakened TFPI's ability to inhibit FXa, it still had some effect on FVIIa/tissue factor activity with the help of another protein (
View Article and Find Full Text PDF

COVID-19 progression often involves severe lung injury, inflammation, coagulopathy, and leukocyte infiltration into pulmonary tissues. The pathogenesis of these complications is unknown. Because vascular endothelium and neutrophils express angiotensin-converting enzyme-2 and spike (S)-proteins, which are present in bodily fluids and tissues of SARS-CoV-2-infected patients, we investigated the effect of S-proteins and cell-cell communication on human lung microvascular endothelial cells and neutrophils expression of P-selectin, markers of coagulopathy, NETosis, and inflammation.

View Article and Find Full Text PDF

Background: Tissue factor pathway inhibitor (TFPI) is an important regulator of coagulation and a link between inflammation and thrombosis. During thrombotic events, TFPI is proteolytically inactivated by neutrophil elastase while bound to neutrophil extracellular traps (NETs). Protein arginine deiminase 4 (PAD4) catalyzes the conversion of arginine to citrulline and is crucial for NET formation.

View Article and Find Full Text PDF

Background: SARS-CoV-2 infection is associated with thrombotic and microvascular complications. The cause of coagulopathy in the disease is incompletely understood.

Methods: A single-center cross-sectional study including 66 adult COVID-19 patients (40 moderate, 26 severe disease), and 9 controls, performed between 04/2020 and 10/2020.

View Article and Find Full Text PDF